Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
Total Valuation
Candel Therapeutics has a market cap or net worth of $223.68M. The enterprise value is $219.52M.
Market Cap$223.68M
Enterprise Value$219.52M
Share Statistics
Candel Therapeutics has 49,269,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,269,670
Owned by Insiders19.60%
Owned by Institutions18.44%
Financial Efficiency
Candel Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is ―.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee0.00
Profits Per Employee-1.45M
Employee Count38
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Candel Therapeutics is 0.00. Candel Therapeutics’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio0.00
PB Ratio4.15
Price to Fair Value4.15
Price to FCF-10.17
Price to Operating Cash Flow-10.17
PEG Ratio0.00
Income Statement
In the last 12 months, Candel Therapeutics had revenue of 0.00 and earned 0.00 in profits. Earnings per share was -1.74.
Revenue0.00
Gross Profit0.00
Operating Income-33.37M
Pretax Income0.00
Net Income0.00
EBITDA-33.37M
Earnings Per Share (EPS)-1.74
Cash Flow
In the last 12 months, operating cash flow was -28.63M and capital expenditures -60.00K, giving a free cash flow of -28.69M billion.
Operating Cash Flow-28.63M
Free Cash Flow-28.69M
Free Cash Flow per Share-0.58
Dividends & Yields
Candel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change-48.39%
50-Day Moving Average6.25
200-Day Moving Average6.52
Relative Strength Index (RSI)42.39
Average Volume (3m)1.05M
Important Dates
Candel Therapeutics upcoming earnings date is Sep 3, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateSep 3, 2025
Ex-Dividend Date―
Financial Position
Candel Therapeutics as a current ratio of 2.77, with Debt / Equity ratio of -105.02%
Current Ratio2.77
Quick Ratio2.77
Debt to Market Cap0.04
Net Debt to EBITDA2.75
Interest Coverage Ratio15.97
Taxes
In the past 12 months, Candel Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Candel Therapeutics EV to EBITDA ratio is -5.49, with an EV/FCF ratio of -6.77.
EV to Sales0.00
EV to EBITDA-5.49
EV to Free Cash Flow-6.77
EV to Operating Cash Flow-6.78
Balance Sheet
Candel Therapeutics has $16.56M in cash and marketable securities with ― in debt, giving a net cash position of -$535.00K billion.
Cash & Marketable Securities$16.56M
Total Debt―
Net Cash-$535.00K
Net Cash Per Share-$0.01
Tangible Book Value Per Share$2.09
Margins
Gross margin is 54.28%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin54.28%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Candel Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.00
Price Target Upside341.18% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-33.79%